Get the Stockscreener App
55.84
4.29%
-2.50
After Hours:
49.40
-6.44
-11.53%
Soleno Therapeutics Inc stock is traded at $55.84, with a volume of 540.41K.
It is down -4.29% in the last 24 hours and up +1.68% over the past month.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
See More
Previous Close:
$58.34
Open:
$58.51
24h Volume:
540.41K
Relative Volume:
0.84
Market Cap:
$2.53B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-18.43
EPS:
-3.03
Net Cash Flow:
$-24.94M
1W Performance:
+1.84%
1M Performance:
+1.68%
6M Performance:
+35.67%
1Y Performance:
+97.38%
1-Day Range:
$55.15
$58.88
1-Week Range:
$53.25
$60.92
52-Week Range:
$26.38
$60.92
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
55.84 | 2.53B | 0 | -38.99M | -24.94M | -3.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
PDUFA target action date for Soleno’s DCCR extended by three months - The Pharma Letter
High Growth Tech Stocks to Watch in November 2024 - Simply Wall St
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire Inc.
FDA delays decision of Soleno’s Prader-Willi syndrome drug - Pharmaceutical Technology
What the Options Market Tells Us About Soleno Therapeutics - Benzinga
FDA extends review of Soleno's Prader-Willi syndrome drug - Investing.com India
Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment - Yahoo Finance
FDA extends review of Soleno's Prader-Willi syndrome drug By Investing.com - Investing.com Canada
Soleno Therapeutics slides after FDA review extension of its Prader-Willi syndrome treatment - Seeking Alpha
Soleno Therapeutics Announces FDA Extension of Review - GlobeNewswire
Capnia stock soars to 52-week high, hits $60 milestone By Investing.com - Investing.com South Africa
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of “Buy” by Brokerages - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Capnia stock soars to 52-week high, hits $60 milestone - Investing.com
495,708 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Bought by Westfield Capital Management Co. LP - MarketBeat
Soleno Therapeutics Reports Q3 Progress and Financials - TipRanks
PERCEPTIVE ADVISORS LLC Reduces Stake in Soleno Therapeutics Inc - GuruFocus.com
Perceptive Advisors LLC Increases Stake in Soleno Therapeutics I - GuruFocus.com
Objective long/short (SLNO) Report - Stock Traders Daily
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 - The Manila Times
Soleno Therapeutics Announces Oral Presentations featuring - GlobeNewswire
Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc - GuruFocus.com
Soleno Therapeutics' SWOT analysis: rare disease stock poised for FDA decision - Investing.com Australia
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation - Yahoo Finance
HC Wainwright Reiterates Buy Rating for Soleno Therapeutics (NASDAQ:SLNO) - MarketBeat
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth - Simply Wall St
Harbor Capital Advisors Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Soleno Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Capnia Inc stock soars to 52-week high, hits $58 mark - Investing.com
(SLNO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Target Price at $69.86 - Defense World
Emerald Advisers LLC Grows Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $73.00 at Oppenheimer - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week High Following Analyst Upgrade - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stake Boosted by Allspring Global Investments Holdings LLC - Defense World
Capnia Inc stock soars to 52-week high of $56.89 amid robust growth By Investing.com - Investing.com South Africa
Soleno Therapeutics shares remain Outperform as analyst lifts price target on updated sales projections - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Capnia Inc stock soars to 52-week high of $56.89 amid robust growth - Investing.com India
Oppenheimer Boosts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $73.00 - MarketBeat
Soleno Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire
(SLNO) Technical Data - Stock Traders Daily
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. - GlobeNewswire
TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors - Barron's
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA - MSN
Prader-Willi Syndrome Market to Drive Growth with Prominent - openPR
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):